Abstract:SummaryThe purpose of the present study was to study the characteristics of epidemic growth factor receptor (EGFR) gene distribution in patients with non-small cell lung cancer (NSCLC), and to detect the mutation rate of EGFR gene by Sanger sequencing and amplification refractory mutation system (ARMS)-PCR. Paraffin-embedded sections of NSCLC tissues from 399 NSCLC patients diagnosed in Renmin Hospital of Wuhan University were collected, 103 of them were detected for exons 18–21 mutation of EGFR by Sanger sequencing method, 296 cases were detected for exons 18–21 mutation by ARMS-PCR method. DNA extraction of both groups was performed with Qiagen QLAamp DNA FFPE Tissue KIT. Comparisons of detection rates between the two methods were conducted by row X list chi-square test. The total mutation rate of EGFR gene detected by Sanger sequencing was 21.4%, exons 18–21 and combined mutation rates were 1.0%, 9.7%, 1.0%, 7.8% and 2.0%, respectively. And the proportions were 4.7%, 45.2%, 4.7%, 36.3% and 9.4% respectively. The total mutation rate detected by ARMS-PCR was 51.4%, exons 18–21 and combined mutation rates were 2.7%, 27%, 1.7%, 18.2% and 1.7%, respectively. The proportions were 5.3%, 52.6%, 3.3%, 35.5% and 3.3% respectively. Further analysis of mutation rate showed that there was significant difference between the two methods in detecting total mutation of EGFR gene (P<0.001). There were significant differences in mutation detection rates of exons 19 and 21 (P<0.001, P<0.05), but there were no significant differences in other exons. And there was no significant difference in mutation detection rates between the two methods. The mutation rate of EGFR gene in NSCLC patients was 50%. And exon 19 deletion was the most common mutation type, followed by exon 21 mutation. Compared with Sanger sequencing method, ARMS method is more sensitive with significant advantages in detecting exon 19 deletions and exon 21 mutations, which can be widely used in clinical detection of EGFR gene mutations. The results of this study will further guide patients with advanced NSCLC to select TKI targeted drugs, and provide clinical diagnostic basis for targeted therapy of NSCLC patients.

[High-Resolution Melting Analysis for the Detection of EGFR Mutations in Circulating DNA of Lung Cancer Patients].

Analytic And Clinical Validation Of An Ultrasensitive, Quantitative Polymerase Chain Reaction Assay For Egfr Mutation Analysis With Circulating Tumor Dna

[The Detection by Denaturing High Performance Liquid Chromatography of Epidermal Growth Factor Receptor Mutation in Tissue and Peripheral Blood from Patients with Advanced Non-Small Cell Lung Cancer].

Real-time PCR Assay with High Resolution Melting for EGFR and BIM Mutation of Lung Cancer.

Ultrasensitive and Quantitative Detection of EGFR Mutations in Plasma Samples from Patients with Non-Small-cell Lung Cancer Using a Dual PNA Clamping-Mediated LNA-PNA PCR Clamp

Comparison of Egfr Signaling Pathway Somatic Dna Mutations Derived from Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology

Highly-selective detection of EGFR mutation gene in lung cancer based on surface enhanced Raman spectroscopy and asymmetric PCR

The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI

Establishment of a Digital PCR Platform for Detection of EGFR T790M Mutation in Plasma Circulating DNA from NSCLC Patients

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

Detection of EGFR Gene Mutation Status from Pleural Effusions and Other Body Fluid Specimens in Patients with Lung Adenocarcinoma

A high-sensitivity detection method for plasma EGFR exon 19 deletion

Comparison of EGFR mutations in blood and tumor tissue samples by allele-specific PCR

Establishment of multiplex allele-specific blocker PCR for enrichment and detection of 4 common EGFR mutations in non-small cell lung cancer

Validation of a highly sensitive Sanger sequencing in detecting EGFR mutations from circulating tumor DNA in patients with lung cancers

Epidermal Growth Factor Receptor Mutations In Plasma Dna Samples Predict Tumor Response In Chinese Patients With Stages Iiib To Iv Non-Small-Cell Lung Cancer

High-resolution Melting Analysis: Applications in Molecular Tumor Testing

A Simple and Rapid Method for Detecting Major Mutations of Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

EGFR Gene Mutation and Methodological Evaluation in 399 Patients with Non-small Cell Lung Cancer

Detection of EGFR mutations in patients with suspected lung cancer using paired tissue-plasma testing: a prospective comparative study with plasma ddPCR assay